View : 22 Download: 0

Polymorphisms of ERCC1 genotype associated with response to imatinib therapy in chronic phase chronic myeloid leukemia

Title
Polymorphisms of ERCC1 genotype associated with response to imatinib therapy in chronic phase chronic myeloid leukemia
Authors
Kong J.H.Mun Y.-C.Kim S.Choi H.S.Kim Y.-K.Kim H.-J.Moon J.H.Sohn S.K.Kim S.-H.Jung C.W.Kim D.H.D.
Ewha Authors
문영철
SCOPUS Author ID
문영철scopus
Issue Date
2012
Journal Title
International Journal of Hematology
ISSN
0925-5710JCR Link
Citation
vol. 96, no. 3, pp. 327 - 333
Indexed
SCIE; SCOPUS WOS scopus
Abstract
DNA repair machinery may contribute to the mechanism of the action in imatinib. We examined the association between the single nucleotide polymorphism (SNP) markers involved in the DNA repair enzyme pathway (ERCC1/2/4/5, XRCC1/2/4/5) and the clinical outcomes following an imatinib therapy in chronic phase chronic myeloid leukemia (CML) patients. A total of 169 Korean patients were included. Of the 19 SNPs from these patients, those with the TT genotype of ERCC1 (rs11615) showed a higher probability of achieving major cytogenetic response [P = 0.002, HR 5.14 (95 % CI 1.83-14.43)], complete cytogenetic response [P = 0.012, HR 3.47 (95 % CI 1.31-9.17)], and major molecular response [P = 0.001, HR 5.71 (95 % CI 2.13-15.30)] than those with CC or CT genotypes. This suggests that SNP markers on ERCC1 may predict the response to imatinib therapy, which proposes the potential involvement of the DNA repair machinery in the mechanism of imatinib action in chronic phase CML. © 2012 The Japanese Society of Hematology. © 2012 The Japanese Society of Hematology.
DOI
10.1007/s12185-012-1142-6
Appears in Collections:
의학전문대학원 > 의학과 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE